地诺孕素对子宫内膜异位症病灶体积的影响  

Effect of Dienogest on the Volume of Endometriosis Lesions

作　　者：孙佳凡 徐炜 朱姝 王秀丽 SUN Jia-fan;XU Wei;ZHU Shu;WANG Xiu-li(Nanjing Medical University,Nanjing 211166,China;Department of Gynecology,The First Affiliated Hospital with Nanjing Medical University,Jiangsu Province Hospital,Nanjing 210029,China)

机构地区：[1]南京医科大学,211166 [2]南京医科大学第一附属医院/江苏省人民医院妇科

出　　处：《国际妇产科学杂志》2024年第3期284-289,共6页Journal of International Obstetrics and Gynecology

基　　金：江苏省卫生计生委2018年度医学科研课题(H2018017);江苏省卫生健康委员会2023年度医学科研立项项目(K2023054)。

摘　　要：子宫内膜异位症(endometriosis,EMs)是导致女性痛经、慢性盆腔痛和不孕症的主要原因之一,EMs的长期管理应最大程度地发挥药物治疗的作用。孕激素类药物是EMs治疗的一线用药,其中地诺孕素(Dienogest)目前已成为EMs长期管理的首选药物。地诺孕素不仅能有效缓解EMs相关疼痛症状和预防术后复发,近年来还被观察到具有一定程度的缩小EMs病灶体积的作用。对于暂未生育的年轻卵巢子宫内膜异位囊肿患者、复发型卵巢子宫内膜异位囊肿患者和疼痛明显的深部浸润型EMs患者,地诺孕素可缩小病灶体积,延缓甚至避免手术。概述地诺孕素对卵巢型EMs和深部浸润型EMs病灶体积的影响,以期为EMs的个体化非手术治疗提供依据。Endometriosis(EMs)is one of the leading causes of dysmenorrhea,chronic pelvic pain and infertility in women,and the long-term management of EMs should maximize the role of drug therapy.Progestogens are the first-line drugs for the treatment of EMs,among which dienogest has now been taken as the first choice of drug for long-term management of EMs.Dienogest not only effectively relieves EMs-associated pain and prevents postoperative recurrence,but also has been observed to reduced EMs lesion volume to some extent.For young patients with ovarian endometriotic cysts who have not yet given birth,patients with recurrent ovarian endometriotic cysts,and patients with deep-infiltrating endometriosis(DIE)who experience significant pain,dienogest can reduce the volume of lesions,delay or even avoid surgery.In this review,we provide an overview of dienogest′s impact on the volume of ovarian EMs and DIE,aiming to provide a basis for individualized nonsurgical treatment of EMs.

关 键 词：子宫内膜异位症 卵巢囊肿 孕激素类 卵巢子宫内膜异位囊肿 深部浸润型子宫内膜异位症 地诺孕素 

分 类 号：R711.71[医药卫生—妇产科学]